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E-mail address: shafaq.sikandar@ucl.ac.uk (S. SikaBrainstem and spinal mechanisms mediating visceral nociception are investigated here using electro-
physiology and immunohistochemistry techniques in a model of acute visceral pain. Colorectal disten-
sion (CRD) produced graded visceromotor responses (VMR) in normal rats, and these were facilitated
by intracolonic mustard oil (MO) that generated acute visceral hyperalgesia. The neuropathic pain drug
pregabalin (PGB) is thought to have state-dependent effects in attenuating neuropathic, but not acute
somatic pain, likely by impairing calcium-channel trafﬁcking. We found that systemic PGB produced
antinociceptive effects on CRD-evoked VMRs in naïve rats lacking pathophysiology and in MO-pretreated
rats. Systemic PGB also signiﬁcantly reduced Fos labelling in lumbosacral spinal cords of rats given nox-
ious repetitive CRD; however, PGB did not alter this measure of neural activity in the brainstem. Differ-
ential brainstem processing of noxious somatic and visceral stimuli may underlie the unique lack of
state-dependent actions of PGB in this visceral pain model. Single-unit recordings in the rostral ventro-
medial medulla (RVM) verify that brainstem processing of somatic and visceral stimuli differs. The effects
of CRD on RVM cells classed as ON, OFF, or NEUTRAL were independent of their somatic responses, with
surprising changes in RVM cell activity to innocuous visceral stimulation. PGB also markedly reduced the
visceral responses of RVM ON-cells to noxious CRD. These results illustrate clear differences in the central
processing of visceral and somatic stimuli, yet a common role for descending modulation by brainstem
activity in mediating evoked pain measures.
 2011 International Association for the Study of Pain. Published by Elsevier B.V.
Open access under CC BY license.1. Introduction
The relative paucity in knowledge of visceral nociceptive signal-
ling compared to somatic pain syndromes leads to major chal-
lenges in the treatment of visceral pain disorders. A better
understanding of the different processes involved in visceral noci-
ception and an assessment of analgesic mechanisms could lead to
more effective visceral pain treatments.
Numerous reports substantiate the clinical efﬁcacy of pregaba-
lin (PGB) in providing pain relief alone or as adjunctive therapy in
neuropathic pain patients [1,2,34,39]. However, the analgesic po-
tential of gabapentinoids in other pain states, including ﬁbromyal-
gia, postoperative pain, and osteoarthritis, has been supported by
animal and clinical studies [13,34,40]. A clinical trial with irritable
bowel syndrome patients suffering from rectal hypersensitivity
showed that PGB increased distension sensory thresholds to nor-
mal levels [26].
Binding to the ubiquitous a2d subunit of voltage-gated calcium
channels is both necessary and sufﬁcient for the analgesic effects oftudy of Pain. Published by Elsevie
ndar).gabapentanoids, and this may impair channel trafﬁcking [3,14,19,
25,28]. In addition, pathological states and resultant interactions
with a spino-bulbo-spinal loop comprising projection neurones in
the superﬁcial dorsal horn and brainstem descending serotonergic
facilitations mediated by 5-HT3 receptors are permissive for gaba-
pentanoid analgesia [5,46]. Together, these state-dependent
changes allow PGB to attenuate neuropathic, but not acute, so-
matic pain.
Disordered descending modulation from the brainstem may
underlie abnormal pain perception in functional somatic and vis-
ceral pain disorders [37,51,52]. Functional imaging shows activa-
tion of the brainstem rostral ventromedial medulla (RVM) during
both visceral and somatic pain [16]. The RVM plays a key role in
central pain modulation and is an important relay for integration
of descending inﬂuences onto the spinal cord. RVM neurones are
classiﬁed based on their ﬁring patterns to noxious somatic stimuli
[20]. ON-cells increase ﬁring immediately before a nocifensive re-
sponse and are presumably pronociceptive; OFF-cells are thought
to mediate inhibition and transiently pause ﬁring prior to a noci-
fensive response; NEUTRAL-cells show no consistent change in ﬁr-
ing to a noxious somatic stimulus, and their role in nociceptive
processing yet remains unclear.r B.V. Open access under CC BY license.
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RVM produces intensity-dependent facilitation or inhibition of
spinal neuronal responses to colorectal distension (CRD) [54,55].
The maintenance of pancreatitis-induced abdominal hypersensi-
tivity is prevented by selective ablation of pronociceptive RVM
cells, likely ON-cells [53]. The RVM can therefore promote excit-
ability that produces visceral pain through mechanisms that may
correspond to the descending RVM facilitations that contribute to
the analgesic actions of PGB [5,46].
We use electrophysiological recordings to compare responses of
RVM neurones to somatic and visceral CRD stimuli to determine
whether brainstem processing, and thereby generation of descend-
ing inﬂuences on spinal excitability, differ between somatic and
visceral signalling. We also investigate whether PGB has analgesic
efﬁcacy in the acute visceral pain model of CRD with and without a
transient visceral hyperalgesia, and we further use RVM recordings
and immunohistochemistry to determine whether and how sys-
temic administration of PGB alters excitatory neural activity cen-
trally in the spinal cord and in the brainstem following CRD.
These studies will assess whether state-dependent actions of PGB
in neuropathy also apply to acute visceral pain.2. Methods
All studies used male Sprague–Dawley rats (250–300 g) sup-
plied by Biological Services Unit (BSU, University College London,
UK). All procedures were approved by the Home Ofﬁce (UK) and
were in agreement with the International Association for the Study
of Pain guidelines [56].
2.1. Colorectal distension
Rats were initially anaesthetized in an induction box with 4%
isoﬂurane in a mixture of N2O (66% v/v) and O2 (33%). A tracheot-
omy was performed once the rats were unconscious and areﬂexic.
The trachea was exposed and a tracheal cannula was inserted and
tied with 3-0 silk thread. Anaesthesia was maintained through the
tracheal cannula throughout the recording period. Rats were se-
cured to a stereotaxic frame with a heating blanket to maintain a
core temperature of 37 C.
The balloon for CRD was made using 7 cm of a latex balloon tied
with silk thread to a cannula perforated throughout a 5-cm tip, and
inserted 1 cm intra-anally. Isoﬂurane was maintained at 1% v/v for
the remainder of the recording period, a level of anaesthesia sufﬁ-
cient to prevent spontaneous movements while maintaining reﬂex
motor controls. CRDs were produced by inﬂating the balloon
through a pressure ampliﬁer to measure the degree of inﬂation
as mm Hg.
2.2. Electromyography recordings
Isoﬂurane was maintained at 1.5% v/v while an incision was
made in the right lower quadrant of the abdomen to expose under-
lying muscle. An enamel-coated copper electrode was sown into
the right external oblique muscle and the incision was sutured
with skin clips.
The recording electrode was inserted into a head stage as part of
a Neurolog system with a 1401 interface and Spike4 software
(Cambridge Electronic Design, Cambridge, UK). Captured signals
from muscle activity were ampliﬁed, ﬁltered, and displayed on
an oscilloscope, and signals were further integrated to produce
electromyography (EMG) values.
CRDs were given in increasing steps of 10 mm Hg from 10 mm
Hg to 80 mm Hg, lasting for 30 seconds, with 3-minute intervals
between each distension and 15-minute intervals between series.The mean integrated EMG values evoked during CRD (visceromotor
responses [VMRs]) were used for further analysis.
Once the average control EMG values were obtained for disten-
sions from 10 mm Hg to 80 mm Hg, PGB was administered subcu-
taneously (30 mg/kg) and series of distensions were performed at
20 and 60 minutes later and evoked VMR recorded.
Reproducibility of the CRD model and evoked VMRs was vali-
dated in preliminary studies by conﬁrming that the evoked VMR
EMG values did not differ more than 15% from the average EMG
control value at 20 and 60 minutes after the EMG control value,
corresponding to PGB administration time points.
2.3. Visceral hyperalgesia
Rats remained anaesthetized with isoﬂurane (1.5%) in a mixture
of N2O (66% v/v) and O2 (33% v/v). A cannula was used to adminis-
ter 1 mL of mustard oil (MO; 0.25% in mineral oil) 1–6 cm intra-
anally.
The isoﬂurane level was reduced to that used in control EMG
recordings, and 30 minutes were allowed for visceral hyperalgesia
to develop before resuming EMG recordings. PGB was adminis-
tered subcutaneously (30 mg/kg) 10 minutes after MO. Series of
distensions were performed and evoked VMR was recorded 20
and 60 minutes after PGB administration (corresponding to 30
and 70 minutes after MO application).
2.4. c-Fos expression
All rats were anaesthetized and a tracheotomy was performed
to maintain anaesthesia with isoﬂurane in a mixture of N2O (66%
v/v) and O2 (33% v/v) for the duration of the experiment, and a
CRD balloon was made and inserted and isoﬂurane was lowered
to 1.0% v/v (see Section 2.1 details).
For the noxious CRD protocol, the balloon was distended to
70 mm Hg for 2 hours (30 seconds on, 90 seconds off). This para-
digm has been shown to result in a signiﬁcant expression of
c-Fos in the lumbosacral cord [50]. For the noxious + PGB protocol,
rats were administered PGB (30 mg/kg subcutaneously) 5 minutes
prior to the 2-hour Noxious distension protocol. Sham rats had
CRD balloons inserted but no distensions given.
At 2 hours following the end of the CRD protocol for c-Fos
induction, rats were deeply anesthetized with 1 mL (200 mg intra-
peritoneally) pentobarbitone sodium (Merial Animal Health Ltd,
Harlow, Essex, UK). The thoracic cage was cut open to expose the
heart, and animals were transcardially perfused with 300 mL saline
(0.9% w/v) in solution with heparin (5000 IU/L saline) (LEO Labora-
tories, Buckinghamshire, UK). This was followed by 300 mL of 4%
paraformaldehyde (VWR, Lutterworth, Leicestershire, UK) in
0.6 M phosphate-buffered solution (PBS).
A laminectomy was performed to expose and remove spinal
cord segments L5-S2, and a craniotomy was performed to expose
and remove the hindbrain. Tissue was postﬁxed for 2 hours before
being transferred to a cryoprotectant solution of 30% w/v sucrose
in 0.1 M PBS and 0.01% w/v sodium azide (Sigma Aldrich, Dorset,
UK) for a minimum of 3 days.
All tissue was cut on a freezing microtome in 40-lm sections,
collected serially and stored in a cryoprotectant solution of 5% w/
v sucrose in 0.1 M PBS and 0.01% w/v sodium azide. Tissue sections
were transferred to Fluorescence-activated cell sorting (FACS)
tubes containing blocking solution made of 3% normal goat serum
in 0.1 M PBS with 10% v/v triton x-100 (Sigma Aldrich) and H2O2
(VWR) and incubated for 1 hour. The blocking solution was re-
placed with the rabbit polyclonal c-Fos primary antibody
(1:20,000 brain sections, 1:60,000 spinal cord sections) (Calbio-
chem, Nottingham, UK) and the tissue was incubated for 24 hours
at room temperature.
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antibody and incubated in biotinylated secondary antibody (Goat
Anti-Rabbit, 1:500 in Tween/Tris-buffered saline (TTBS)) for
2 hours. Following another round of washes, tissue sections were
incubated in ABC (1:1000 TTBS Vectastain A, 1:1000 Vectastain
B) for 1 hour. Tissue sections were washed again to remove excess
AB complex, and conventional 3,30-diaminobenzidine (DAB) stain-
ing (DAB substrate kit, Vector Laboratories, Burlingame, CA, USA)
in the presence of hydrogen peroxide was used to reveal Fos
immunoreactivity. Accordingly, tissue sections were incubated in
DAB for 10–15 minutes before being transferred to distilled water
for 5 minutes to stop the peroxidase reaction. Tissue sections were
transferred to 0.1 M PBS before being mounted onto gelatinized
slides. Slides were allowed to dry overnight, and were dehydrated
the following day, coverslipped with DPX mounting agent (VWR),
and sealed with nail varnish.
2.5. RVM recordings
Following the tracheotomy (see CRD details), the skull was ex-
posed to mark positions of lambda and bregma. The incisor bar was
adjusted (3.9 ± 0.5 mm) below horizontal zero until heights of
bregma and lambda were equal to achieve the ﬂat skull position.
An area correlating to the RVM was marked and drilled 2 mm in
diameter and the dura removed.
A CRD balloon was made and inserted. Isoﬂurane was slowly
lowered to 1.2% v/v with O2 alone over a 1-hour period. Once the
rats were stabilized at an anaesthetic level sufﬁcient to maintain
reﬂex withdrawal from pinching the paw and tail, a recording elec-
trode (parylene-insulated tungsten microelectrode, 12-lm diame-
ter, 2 MO; A-M Systems Inc, Carlsborg, WA, USA) was inserted into
the RVM (0.0–0.9 mm mediolateral, 10.5–11.5 mm caudal from
bregma, 9.0–11.0 mm dorsal from dura matter).
The recording electrode was inserted into a head stage as part
of a Neurolog system with a 1401 interface and Spike4 software
(Cambridge Electronic Design). Neuronal activity was ampliﬁed,
ﬁltered, and displayed on an oscilloscope and made audible
through speakers. Single neurones were isolated based on good
signal-to-noise ratios and common action potential shapes.
RVM cells were identiﬁed as ON, OFF, or NEUTRAL according
to their change in ﬁring following a noxious thermal stimulus
(55 C immersion of 8 cm of the tail), in terms similar to those
described by Fields et al. [20]. The relative change in ﬁring in-
duced by noxious heat was measured as spikes following the re-
ﬂex tail ﬂick subtracted by baseline ﬁring (5 seconds of activity
after the tail ﬂick minus 5 seconds of activity prior to the tail
ﬂick). The classiﬁcation of ON-, OFF-, and NEUTRAL-cells was
based on a >15% change in baseline ﬁring.
Once an RVM cell had been characterised according to somatic
responses with tail heat, its responses to CRDs were determined.
Again, changes >15% of the baseline ﬁring determined whether
cells were classiﬁed as ON, OFF, or NEUTRAL to visceral stimulation
(20 seconds of activity during CRD subtracted by 20 seconds of
activity prior to CRD). CRDs were given as innocuous (20 mm Hg)
or noxious (70 mm Hg) visceral stimuli lasting 20 seconds, with a
3-minute interval between each distension. A pressure ampliﬁer
converted signals from the distending balloon to mm Hg. The rel-
ative numbers of spikes evoked during the 20-second CRD period
subtracted by a 20-second baseline were used for further analysis.
2.6. Statistical analysis
EMG values were integrated with subtracted baselines and
postdrug data were normalized for each animal to the mean
control EMG values. Normalized EMG data were evaluated with
both the Kolmogorov–Smirnov (with Dallal–Wilkinson–LillieforP value) and the D’Agostino and Pearson omnibus normality
tests to conﬁrm that data were normally distributed and there-
fore eligible for analysis of variance (ANOVA) with Bonferroni
post-tests. A 2-way ANOVA with repeated measures and Bonfer-
roni post-tests was used to determine statistical signiﬁcances
throughout the range of CRD pressures between the 3 recording
time points for the PGB time course in normal rats and MO-
treated rats. For area-under-curve analysis, a 1-way ANOVA with
Bonferroni post-tests was used to determine statistical differ-
ences between groups. Similarly, a 2-way ANOVA with repeated
measures and Bonferroni post-tests was used to determine the
statistical signiﬁcances between noxious or innocuous CRD-
evoked RVM neuronal activity throughout the PGB time course.
A 1-way ANOVA with Bonferroni post-tests was used to deter-
mine statistical differences among evoked activities during the
4 recording points in the PGB time course.
For Fos immunohistochemistry, analysis of labelled neurones in
both brain and spinal cord sections involved 4 animals in each
group (Sham distension, Noxious distension, Noxious distension
with PGB, and Sham distension with PGB) and 5 tissue sections
per animal. A 1-way ANOVA with Bonferroni post-tests was used
to determine the signiﬁcant difference between numbers of Fos-
labelled neurones quantiﬁed in the 3 groups using both RVM and
L6-S1 sections.3. Results
3.1. Validation of CRD model and pregabalin modulation of VMRs
A reproducible model of visceral pain is illustrated by the
graded evoked VMRs following increasing CRD pressures. Stability
of VMRs is demonstrated using saline injections with VMRs mea-
sured 20 and 60 minutes after administration (Fig. 1A).There is
no signiﬁcant change in VMR during this recording period (time
variable F[2,80] = 1.539, P > 0.05; pressure variable F[7,80] =
29.79, P < 0.0001). Moreover, we also show that the VMR can be
pharmacologically manipulated (Fig. 1B). Morphine dramatically
reduces VMR evoked by the full range of CRD pressures, and this
morphine-induced inhibition is reversed by administration of nal-
oxone (F[2,11] = 25.86, P < 0.0001).
Control-evoked VMRs show clear, graded responses with mag-
nitudes correlating to increasing CRD pressures from 10 mm Hg
to noxious CRD of 80 mm Hg (Fig. 1C). Systemic administration
of PGB in naïve rats dramatically reduces the evoked VMR through-
out the noxious CRD pressure range of 30 mm Hg to 80 mm Hg
CRD stimuli at 20 minutes and further at 60 minutes post-PGB
(Fig. 1D); (F[2,15] = 67.66, P < 0.0001).
3.2. PGB modulation of visceral hyperalgesia
PGB also prevents the development of potentiated VMRs in rats
pretreated with intracolonic MO (Fig. 2A) (time variable
F[2,64] = 33.88, P < 0.0001; pressure variable F[7,64] = 7.358,
P < 0.0001). Visceral hyperalgesia is illustrated by a time-
dependent potentiation of evoked VMR peaking at 30 minutes
post-MO and declining to control VMR values at 70 minutes
post-MO (Fig. 2B) (F[8,9] = 55.88, P < 0.0001). There is no signiﬁ-
cant difference between control VMRs and VMRs evoked at the
20-minute recording point in the MO + PGB group at any CRD pres-
sure, illustrating a complete inhibition of the potentiation response
by PGB. Moreover, PGB dramatically reduces the evoked VMR at
the 60-minute MO + PGB time point, illustrating long-lasting
inhibitory actions of PGB as in naïve animals. Thus, PGB has inhib-
itory actions on noxious evoked VMRs in normal animals and in
animals with visceral hypersensitivity.
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Fig. 1. Pregabalin (PGB) reduces visceromotor response (VMR) throughout the noxious range of colorectal distension (CRD) pressures in naïve rats. (A) Line graphs
representing evoked VMRs by a range of innocuous to noxious CRD pressures to illustrate the stability and reproducibility of VMRs. There is no signiﬁcant change in VMR
between baseline control and following control saline administration at 20 and 60 minutes (n = 5). (B) Area-under-curve bar graphs of overall evoked VMRs in naïve rats
(n = 9) illustrate the dramatic reduction in VMR by the full range of CRD pressures by morphine (2.5 mg/kg subcutaneously [s.c.]), and the reversal of this morphine-induced
inhibition by naloxone (2 mg/kg s.c., ⁄⁄⁄P < 0.001). (C) Line graphs representing evoked VMRs by a range of innocuous-to-noxious CRD pressures for the 3 recording points in
the PGB time course in naïve rats (n = 6; 30 mg/kg s.c.). Sixty minutes after PGB administration, the evoked VMR is reduced dramatically over the 30-mm-Hg to 80-mm-Hg
CRD pressures, corresponding to the noxious range of colonic distension (⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 control vs. 60 minutes). (D) Area-under-curve comparisons of the
evoked VMR illustrate an overall signiﬁcant reduction throughout both the 20- and 60-minute recordings after PGB administration (⁄⁄⁄P < 0.001).
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Fig. 2. Pregabalin prevents development of visceral hyperalgesia induced by intracolonic mustard oil (MO). (A) Line graphs representing evoked visceromotor responses
(VMRs) by a range of innocuous to noxious colorectal distension (CRD) pressures for the 3 recording points in the pregabalin (PGB) time course (30 mg/kg subcutaneously) in
rats pretreated with intracolonic MO to induce visceral hyperalgesia (n = 7; ⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001 control vs. 60 minutes; ^P < 0.05, ^^P < 0.01 20 vs. 60 minutes). (B)
Collective area-under-curve data of groups with PGB alone (n = 6), with intracolonic MO alone (n = 8), and with PGB and intracolonic MO pretreatment (n = 7). Rats with
intracolonic MO show a transient potentiation of evoked VMR that is lost in rats also given systemic PGB (⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001).
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Noxious CRD markedly increases the number of c-Fos-labelled
neurones compared to sham CRD both in L6-S1 spinal cord sections
(Fig. 3) and in brainstem RVM sections (Fig. 4). In the spinal cord,
the increase in Fos immunoreactivity is generalized throughout
the dorsal and ventral horns (lamina I–II F[3,16] = 114.1,
P < 0.0001; lamina III–V F[3,16] = 74.75, P < 0.0001; lamina VI–VIIFig. 3. c-Fos expression is higher following noxious colorectal distension (CRD) in L6-
photomicrographs of L6-S1 spinal cord sections in the 4 treatment groups: sham CRD (SH
sham CRD with PGB (SHAM + PGB; 30mg/kg s.c.). Arrows indicate Fos-labelled neurone
tissue of sham CRD (SHAM), noxious CRD (NOX), noxious CRD with PGB (NOX + PGB) an
spinal cord (superﬁcial dorsal horn: laminae I–II [B1], deep dorsal horn: laminae III–V
central canal: lamina X [B5]). Noxious CRD markedly increases c-Fos labelling in all quan
reduced by PGB in throughout the dorsal and ventral regions (⁄P < 0.05, ⁄⁄⁄P < 0.001). ScF[3,16] = 37.86, P < 0.0001; lamina X F[3,16] = 79.36, P < 0.0001).
This would be expected since sensory neurones in the dorsal horn
would be activated by visceral afferent activity, in turn activating
ventral horn neurones that are responsible for the observed mus-
cular contractions. PGB administration signiﬁcantly reduces the
overall noxious CRD-induced increase in Fos counts in the spinal
cord effectively to control values. In contrast, PGB does not alter
Fos immunoreactivity in the RVM (F[3,16] = 15.55, P < 0.0001). InS1 and is signiﬁcantly reduced by systemic pregabalin (PGB). (A) Representative
AM), noxious CRD (NOX) and noxious CRD with PGB (NOX + PGB; 30 mg/kg s.c.) and
s. (B) Numbers of c-Fos-labelled neurones in different regions of L6-S1 spinal cord
d sham CRD with PGB (SHAM + PGB) rats are illustrated for different regions of the
[B2], intermediate region: laminae VI–VII [B3], ventral horn: laminae VIII–IX [B4],
tiﬁed regions of the spinal cord compared to innocuous CRD, and this is signiﬁcantly
ale bars = 100 lm.
Fig. 4. Levels of c-Fos expression are higher following noxious colorectal distension (CRD) in the rostral ventromedial medulla (RVM) but are unchanged after systemic
pregabalin (PGB). (A) Representative photomicrographs of RVM sections in the 4 treatment groups: sham CRD (SHAM), noxious CRD (NOX), and noxious CRD with PGB
(NOX + PGB; 30 mg/kg and sham CRD with PGB (SHAM + PGB; 30mg/kg s.c.). Arrows indicate c-Fos-labelled neurones. (B) Numbers of c-Fos-labelled neurones in RVM tissue
of the sham CRD (SHAM), noxious CRD (NOX), noxious CRD with PGB (NOX + PGB) and sham CRD with PGB (SHAM + PGB) rats. Noxious CRD dramatically increases c-Fos cell
counts, yet this level of c-Fos expression is unchanged with PGB administration (⁄⁄⁄P < 0.001). Scale bars = 100 lm.
S. Sikandar, A.H. Dickenson / PAIN

152 (2011) 2312–2322 2317both RVM tissue and spinal cord tissue, there is no signiﬁcant dif-
ference between the SHAM group and the SHAM + PGB group, so
PGB is only reducing noxious-evoked activity.
3.4. Physiological responses of RVM neurones to somatic and visceral
stimuli and PGB effects on RVM neural activity
Electrophysiological recordings in the brainstem illustrate that
RVM ON-, OFF-, and NEUTRAL-cells show characteristic changes
in reﬂex-related ﬁring following the onset of the noxious somatic
heat stimulus to tail (Fig. 5). Accordingly, ON-cells increase
reﬂex-related ﬁring following noxious tail heat; OFF-cells pause
reﬂex-related ﬁring following noxious tail heat; NEUTRAL-cells
show no consistent change in reﬂex-related activity following nox-
ious tail heat. In contrast, the recordings of neuronal activity dur-
ing visceral CRD stimuli do not display changes consistent with
this somatic-based classiﬁcation, as RVM ON-, OFF-, and even NEU-
TRAL-cells display changes in activity to innocuous (as well as nox-
ious) visceral stimulation, and also variably increase, decrease, or
show no change in ﬁring during CRD (Fig. 6). The RVM neural pro-
cessing of somatic and visceral stimuli must thus differ. The
changes in cell ﬁring are greater during noxious CRD stimulation
compared to innocuous CRD. Accordingly, more ON-, OFF-, and
NEUTRAL-cells responded to noxious CRD compared to innocuous
CRD. Ninety percent of ON-cells, 89% of OFF-cells, and 60% of NEU-
TRAL-cells display >15% changes in baseline spike activity during
70-mm-Hg CRD, compared to 55%, 71%, and 40%, respectively, dur-
ing 20-mm-Hg CRD. The greater variability of responses during
noxious CRD stimulation reﬂects the increased magnitudes of ﬁr-
ing of ON-, OFF-, and NEUTRAL-cells compared to innocuous CRD.
Thus, control responses of RVM ON-cells during noxious CRD
prior to PGB administration at time 0 are signiﬁcantly greater than
responses to innocuous CRD (Fig. 7) (F[3,60] = 4.402, P < 0.01). Fol-lowing PGB administration, the ﬁring of RVM ON-cells during
noxious CRD is dramatically inhibited throughout the 20-, 40-,
and 60-minute recording periods (F[3,7] = 7.493, P < 0.0001). This
is similar to the 60-minute time frame of PGB reductions of overall
evoked VMR in naïve rats. However, PGB does not have any signif-
icant inhibitory effect on the responses of ON-cells during innocu-
ous CRD (F[3,7] = 1.367, P > 0.05).
Only the effects of PGB on ON-cell activity were fully analyzed.
Despite strenuous efforts, we were unable to record, for sufﬁciently
long periods, OFF-cell responses to visceral stimuli. However, PGB
did reduce the magnitude of the pause in activity of 2 medullary
cells that had OFF-like responses to CRD. Cellular recording sites
were stereotaxically deﬁned (Fig. 8).4. Discussion
Graded visceromotor responses to CRD measured with EMG
recordings are attenuated by systemic PGB both in normal animals
and in rats with MO-induced hypersensitivity at doses that are
effective in neuropathic models [5]. Marked differences in nocicep-
tive modulation of somatic structures and viscera are illustrated by
this efﬁcacy of PGB in reducing acute visceral nociception, com-
pared to its state-dependent actions in neuropathy, where PGB
has little effect in naïve animals but attenuates pain measures in
animals with somatic pathology. We also show a differential brain-
stem processing of somatic and visceral sensory information,
where the deﬁnition of RVM ON-, OFF-, and NEUTRAL-cells (by so-
matic stimuli) does not predict their responses to visceral innocu-
ous and noxious CRD stimuli. PGB attenuates excitatory responses
of RVM neurones to noxious visceral stimuli.
Systemic PGB signiﬁcantly reduces evoked visceral pain in nor-
mal rats and in rats with a transient visceral hyperalgesia,
Fig. 5. Rostral ventromedial medulla (RVM) ON-, OFF-, and NEUTRAL-cells display characteristic changes in reﬂex-related ﬁring following a noxious somatic stimulus. (A)
Example trace of an RVM ON-cell that increases reﬂex-related ﬁring following noxious tail heat (H = onset of heat stimulus, T = tail ﬂick). (B) Example of a ratemeter trace of
an RVM OFF-cell that pauses reﬂex-related ﬁring (spikes) following noxious tail heat. (C) Example trace of a NEUTRAL-cell that displays no consistent change in reﬂex-related
activity following noxious tail heat.
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a rangeof distensions (10–80 mmHg) reportedpreviously following
PGB administration [41]. This nociceptive-speciﬁc efﬁcacy of PGB
correlates with previous behavioural ﬁndings of similar systemic
doses of PGB reducing evoked VMRs following noxious CRD [18,33].
PGB likely exerts analgesic effects in the CRD model by modula-
tion of calcium channel function, although interactions with upreg-
ulated calcium channel subunits after neuropathy [30] may not
extend to all pain states. Gabapentanoids exert inhibitory actions
in short-term inﬂammatory models [18,43] and the CRD model
presented here, where a2d upregulation has insufﬁcient time to oc-
cur. In contrast, gabapentanoids do not change spinal neuronal re-
sponses to nociceptive mechanical or thermal somatic stimuli in
normal animals, but are efﬁcacious in chronic pain models of neu-
ropathy and osteoarthritis [5,40,46]. This minimal modulation of
normal synaptic transmission in the dorsal horn [17,40,46], but
modulation of central-hyperalgesic states [15,27,43] is supported
by functional magnetic resonance imaging data showing that gaba-
pentin has a state-speciﬁc modulation of brainstem activation only
in the presence of central sensitisation [27]. Sufﬁcient central
excitability as a prerequisite for the analgesic efﬁcacy of PGB could
develop as central sensitisation following persistent or sufﬁcient
peripheral afferent barrage into the CNS [12]. Although central sen-
sitisation is mainly described as a spinal cord phenomenon involv-
ing N-methyl-d-aspartate receptor activity, supraspinal structures
also contribute to its development and maintenance [12,52].
As visceromotor responses to acute CRD stimuli are produced
by lumbosacral-bulbo-spinal loops [35], consequent spinal and
brainstem activation may produce a permissive state of centralexcitability for systemic PGB to exert inhibitory actions in naïve
rats or in rats with acute inﬂammation [18,33,41].
Further evidence for differential central processing of visceral
and somatic stimuli is the contrasting changes in brainstem activ-
ity to visceral and somatic stimulation. Functional magnetic reso-
nance imaging reveals equivalent bilateral activation of the
periaqueductal grey or RVM following somatic and visceral stimu-
lation [16]. This highlights a role for the RVM in nociceptive pro-
cessing of both somatic and visceral sensory transmission in
humans. Importantly, our electrophysiological recordings of RVM
neurones in the CRD model reveal that reﬂex-related activity of
ON-, OFF-, and NEUTRAL-cells to noxious somatic stimuli is not
predictive of changes in activity of these cells during visceral stim-
ulation [20]. The ﬁndings that RVM neurones do not respond in the
same direction to visceral and cutaneous stimulation, but show
similar changes in absolute magnitude, is consistent with previous
observations of RVM cell responses to CRD in rats [8,9] and to blad-
der stimulation in the cat [10]. We have also shown that the
ambiguous role of NEUTRAL-cells in modulating somatic noxious
signalling is contrasted by direct increases or decreases in reﬂex-
related ﬁring of these cells following visceral stimulation.
Therefore, RVM neurones can have independent, multi-
directional responses to and effects on visceral and somatic noci-
ceptive processing. This may underlie spinal mechanisms of viscer-
osomatic convergence as well as heterotopic antinociception
demonstrated by CRD-evoked suppression of cutaneous
withdrawal reﬂexes [7].
Surprisingly, in contrast to responding almost exclusively to
noxious cutaneous stimuli in normal animals [20,29], these RVM
Fig. 6. The responses of rostral ventromedial medulla (RVM) ON-, OFF-, and NEUTRAL-cells to noxious somatic stimuli do not predict changes in reﬂex-related ﬁring
following innocuous and noxious visceral stimuli. (A) Changes in activity of RVM ON-cells during innocuous (20 mmHg) and noxious (70 mmHg) colorectal distension (CRD),
measured as number of spikes differing from baseline (n = 44). (B) Changes in activity of RVM OFF-cells during innocuous (20 mm Hg) and noxious (70 mm Hg) CRD (n = 17).
(C) Changes in activity of RVM NEUTRAL-cells during innocuous (20 mm Hg) and noxious (70 mm Hg) CRD (n = 14). Upper and lower quartiles, median number of spikes, and
standard deviation are noted with the graphs. Numbers of ON, OFF, and NEUTRAL-cells behaving in an ON, OFF, or NEUTRAL-like fashion to CRD stimulation are also noted. (D)
An example ratemeter trace of an OFF-cell that increases ﬁring to innocuous CRD and (E) to noxious CRD. (F) An example ratemeter trace of an ON-cell that increases ﬁring to
innocuous CRD and (G) to noxious CRD.
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Hg CRD, a nonaversive visceral stimulus in awake rats [8,9]. The re-
sponses of RVM neurones to innocuous visceral stimulation may be
related to distension pressure coding of low-threshold mechano-
sensitive visceral afferents that also code noxious stimuli [42].
Importantly, this elaborated heterogeneity of RVM neurones
emphasizes differences in the central neuronal and, speciﬁcally,
brainstem processing of somatic and visceral signals, which may
further contribute to different physiological prerequisites for the
analgesic efﬁcacy of PGB in somatic and visceral pain states.
We showed that ﬁring of a subset of RVM ON-cells, speciﬁcally
neurones that also increased ﬁring to CRD, was reduced with sys-
temic PGB. Because these ON-cells increase ﬁring to both somatic
and visceral stimulation, they likely have a pronociceptive, facilita-
tory role in both somatic and visceral nociceptive processing. This
supports numerous ﬁndings of pronociceptive RVM ON-cell activ-
ity [4,23,24,36].c-Fos expression in the spinal cord and RVM following noxious
repetitive CRD was reduced throughout the ventral and dorsal
horns and central canal by PGB. These spinal cord regions are all
innervated by the RVM [21], although the parallel reduction in
ventral and dorsal horn Fos labelling is likely to indicate a primary
PGB depression of sensory neurotransmission in the dorsal horn
that secondarily drives a reduction in ventral horn neuronal activ-
ity and motor output. This corresponds with other electrophysio-
logical studies reporting reductions in sensory-evoked responses
of spinal neurones of animals with neuropathy following PGB
administration [5]. Here again, PGB is effective in reducing visceral
Fos labelling in normal animals.
The PGB effects on RVM ON-cell neuronal activity, yet the lack
of change in RVM Fos-labelling, could be explained by Fos labelling
not being able to distinguish between neural activity related to
nociceptive processing and antinociception [22]. These results
can be explained by different subsets of RVM neurones producing
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Fig. 7. Pregabalin (PGB) inhibits noxious colorectal distension (CRD)-evoked
activity of rostral ventromedial medulla (RVM) ON-cells that are also excited by
noxious CRD, but does not affect the innocuous CRD-evoked activity. Recordings
made from RVM ON-cells that increase ﬁring to both noxious somatic and
innocuous and noxious CRD visceral stimulation (n = 11). Bar graphs illustrate the
change in activity during innocuous (20 mm Hg) and noxious (70 mm Hg) CRD of
RVM ON-cells before and after systemic PGB administration (30 mg/kg subcutane-
ously) (⁄P < 0.05, ⁄⁄P < 0.01).
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guished by Fos. Furthermore, Fos-negative neurones could encode
signiﬁcant amounts of nociceptive information in the brainstem.
Thus, if PGB increased OFF- and decreased ON-cell activity in equal
proportions, there would be consequent antinociceptive effects on
spinal processing and inhibition of evoked VMRs, yet no change inFig. 8. Rostral ventromedial medulla (RVM) recording sites. A diagrammatic representatio
and NEUTRAL-cells indicated. Coronal depth is evaluated by the dorsoventral distance fr
skull. Every ﬁfth ON-cell and every third OFF- and NEUTRAL cell have been indicated for
within RVM anatomical boundaries.labelling would be seen. We show that systemic PGB reduces
evoked neural activity in the spinal cord and excitatory RVM neu-
ronal activity, although its direct central sites of action are un-
known. Thus, RVM effects could be secondary to altered activity
at spinal levels.
We characterized RVM neurones using isoﬂurane and oxygen,
and RVM cell types corresponded in all regards to those described
by others using halothane or pentobarbital and methohexital
[8,11]. The addition of N2O during c-Fos induction could have af-
fected results, but we observed a clear inhibition of both EMG
and Fos labelling at the spinal level. Thus, any effect of N2O would
have to be selective for RVM, but as stated above, we saw clear
inhibitory effects of PGB on ON-cell activity at this level.
In models of neuropathy and ostearthritis, gabapentanoid
modulation depends on the permissive pathological state involv-
ing speciﬁc interactions with descending serotonergic facilita-
tions mediated by brainstem-spinal mechanisms and
hypothesized interplay between presynaptic 5-HT3 receptors
and a2d subunits of voltage-gated calcium channels [5,46]. This
is substantiated by the upregulation of a2d1 subunits in ipsilat-
eral dorsal root ganglia in neuropathy and osteoarthritis [3,40],
with concomitant serotonergic 5-HT3 receptor-mediated facilita-
tions that both increase spinal excitability and allow gabapenta-
noid actions [40,45].
In models of peripheral nerve injury, spinal and supraspinal
administration of gabapentin is effective [46–49]. Supraspinal
PGB actions involve activation of the descending inhibitory norad-
renergic system in the locus coeruleus [47,48]. Spinal gabapentin
produces analgesic effects through mechanisms that do not elicit
or depend on this supraspinal-evoked noradrenaline release
[47,49]. Given the reciprocal nature of neural connections between
serotonin-rich nuclei of the RVM and noradrenergic nuclei of the
dorsolateral pontine tegmentum [32,38], it is also possible thatn of coronal sections corresponding to RVM nuclei with recording sites of ON-, OFF-,
om the horizontal plane passing through bregma and lambda on the surface of the
clarity due to large n numbers in each group. All recorded cells used for analysis lie
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rect effects on RVM neurones or vice versa, so PGB dually alters
both descending serotonergic and noradrenergic controls to mod-
ulate spinal nociceptive hyperexcitability in naïve and pathological
states [6]. In addition, direct spinal actions could secondarily re-
duce brainstem nociceptive processing.
In conclusion, PGB reduces spinal and brainstem activity, and its
analgesic actions are not dependent on pathology in visceral pain.
A common effect of PGB in visceral and somatic pain states entails
a reduction in central nociceptive hyperexcitability. This may in-
volve interactions with the balance of descending modulation from
the brainstem, where enhanced descending facilitatory controls (or
a reduction in inhibitory inﬂuences) produced by acute visceral
stimuli or somatic insult produce a permissive physiological state
of central excitability for PGB to exert inhibitory actions. This could
also underlie the analgesic efﬁcacy of PGB in other pain states that
develop in lack of any clear peripheral insult, such as irritable bo-
wel syndrome and ﬁbromyalgia [26,44], and effects on limbic func-
tion may relate to anxiolytic actions [31]. Here, central plastic
changes in the spinal cord and higher centres that modulate
descending controls and contribute to central excitability could
both amplify nociceptive transmission and produce interacting
comorbidities. The hypersensitivities that develop consequently
in tandem can potentially be neutralized by central PGB inhibitions
of neural activity.
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